FK949E + Placebo

Phase 2/3Completed
0 views this week 0 watching💤 Quiet
Interest: 38/100
38
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bipolar Disorder

Conditions

Bipolar Disorder

Trial Timeline

Feb 7, 2012 → Jul 11, 2016

About FK949E + Placebo

FK949E + Placebo is a phase 2/3 stage product being developed by Astellas Pharma for Bipolar Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT01725308. Target conditions include Bipolar Disorder.

What happened to similar drugs?

20 of 20 similar drugs in Bipolar Disorder were approved

Approved (20) Terminated (3) Active (0)
Olanzapine + PlaceboEli LillyApproved
OlanzapineEli LillyApproved
OlanzapineEli LillyApproved
olanzapine + risperidoneEli LillyApproved
Topiramate + PlaceboEli LillyApproved

Hype Score Breakdown

Clinical
15
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01725308Phase 2/3Completed

Competing Products

20 competing products in Bipolar Disorder

See all competitors
ProductCompanyStageHype Score
OlanzapineEli LillyPhase 3
32
Valproate + Lithium + Risperidone + OlanzapineEli LillyPhase 3
40
Olanzapine + PlaceboEli LillyApproved
43
FK949EAstellas PharmaPhase 3
40
FK949EAstellas PharmaPhase 3
40
Escitalopram + Bupropion XLLupin LimitedPhase 3
32
OlanzapineEli LillyApproved
43
Olanzapine Hydrochloride + Lithium CarbonateEli LillyPhase 3
40
olanzapine + lithium + valproate + carbamazepineEli LillyPhase 3
40
OlanzapineEli LillyApproved
43
OlanzapineEli LillyPhase 3
40
LY2979165 + PlaceboEli LillyPhase 1
29
olanzapine + divalproex sodium + placeboEli LillyApproved
43
olanzapine + risperidoneEli LillyApproved
43
LY2979165 + placeboEli LillyPhase 1
29
Topiramate + PlaceboEli LillyApproved
43
olanzapineEli LillyPhase 3
40
Olanzapine + PlaceboEli LillyPhase 3
40
Brenipatide + PlaceboEli LillyPhase 2
42
Olanzapine Fluoxetine Combination (OFC) + PlaceboEli LillyApproved
43